How to Get Fosamax (Alendronate) in California

What Is Alendronate and Why It Matters for California Patients

Alendronate is an oral bisphosphonate that suppresses osteoclast-mediated bone resorption, preserving bone mineral density (BMD) and reducing fracture risk in people with osteoporosis or osteopenia with high fracture probability. The Fracture Intervention Trial (FIT), published in JAMA 1998 (N=2,027), demonstrated that alendronate reduced hip fracture risk by 51% and vertebral fracture risk by 47% over three years in postmenopausal women with low femoral neck BMD 1.

Osteoporosis affects roughly 10.2 million Americans, and an additional 43.4 million have low bone mass, according to the National Institutes of Health 2. In California, an estimated 1.3 million women over 50 are living with osteoporosis, making accessible prescribing pathways a genuine public-health concern.

The FDA first approved alendronate under the brand name Fosamax in September 1995 for postmenopausal osteoporosis 3. Multiple generic manufacturers now produce the 70 mg weekly tablet, driving the cash price below $15 at most California pharmacies.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines designate alendronate as a first-line agent for postmenopausal osteoporosis and male osteoporosis 4. The drug's long skeletal half-life (more than 10 years) means that patients who complete a five-year course may safely take a drug holiday before reassessment.

Who Can Prescribe Fosamax in California

Any California-licensed prescriber with independent or delegated prescribing authority may write an alendronate prescription. This includes physicians (MD and DO), nurse practitioners (NP) operating under California Business and Professions Code 2837.103, physician assistants (PA) under supervising or collaborative agreements, and clinical pharmacists holding an advanced practice pharmacist (APh) license under California Business and Professions Code 4052.2 5.

California expanded NP independent practice authority under AB 890, signed into law in 2020. Fully independent NPs, those with at least three years of physician-supervised experience after initial licensure, may prescribe Schedule II through V controlled substances and all non-controlled drugs, including alendronate, without a supervising physician 6.

For telehealth encounters, the prescriber must still hold an active California license. The California Telehealth Advancement Act (2011) and subsequent amendments allow a valid prescriber-patient relationship to be established via synchronous audio-video visits, provided the clinician can form an appropriate clinical judgment and document the encounter 7.

Dentists do not prescribe alendronate, though they play a role in pre-treatment clearance given the small but real risk of medication-related osteonecrosis of the jaw (MRONJ).

How to Get a Fosamax Prescription Through Telehealth in California

California telehealth providers can prescribe alendronate without an in-person visit, provided three conditions are met. First, the patient must supply prior records, ideally a DXA scan report showing T-score at or below -2.5 (osteoporosis) or FRAX 10-year major osteoporotic fracture probability at or above 20%. Second, recent labs (within 90 days) covering serum calcium, 25-OH vitamin D, creatinine, and eGFR must be available. Third, the synchronous audio-video visit must be documented in a California-compliant electronic health record 8.

The typical telehealth workflow at HealthRX and comparable California-licensed platforms runs as follows. The patient completes an intake form, uploads their DXA report and lab results, schedules a 20-to-30-minute video visit, and, if appropriate, receives an electronic prescription sent directly to a California-licensed pharmacy. Turnaround from intake to prescription is commonly 24 to 72 hours.

Patients without a prior DXA scan can be referred to an outpatient imaging center for scheduling, and some telehealth platforms coordinate the referral. The United States Preventive Services Task Force recommends DXA screening for all women aged 65 and older and for younger postmenopausal women whose 10-year fracture probability, calculated by FRAX, equals or exceeds that of a 65-year-old white woman with no additional risk factors 9.

HealthRX Telehealth Readiness Framework for Alendronate Prescribing in California

| Readiness Item | Acceptable Minimum | Preferred | |---|---|---| | DXA scan age | <24 months | <12 months | | Serum calcium | Within 90 days, normal range | Within 30 days | | 25-OH vitamin D | Within 90 days | Within 30 days, >30 ng/mL | | eGFR | Within 90 days, >35 mL/min | Within 30 days | | Dental exam | Within 12 months | Within 6 months | | FRAX score | Calculated at visit | Calculated with BMD input | | California pharmacy on file | Required | With auto-refill enrollment |

Required Labs and Workup Before Starting Alendronate in California

Before alendronate is prescribed, four baseline tests are standard across California clinical practice and align with AACE 2020 guidance 4. Serum calcium must be within normal limits because bisphosphonates can transiently lower ionized calcium, and pre-existing hypocalcemia is a contraindication. Vitamin D status (25-OH vitamin D) is checked because deficiency blunts the drug's antiresorptive effect; most California clinicians target a level above 30 ng/mL before initiation 10. Serum creatinine and the calculated eGFR are checked because alendronate is contraindicated when eGFR falls below 35 mL/min/1.73 m², a threshold established in the FDA label 3.

A complete metabolic panel is often ordered at the same time to screen for secondary causes of bone loss such as hypercalcemia of malignancy or primary hyperparathyroidism 11. Some endocrinologists also order thyroid-stimulating hormone (TSH) to rule out subclinical hyperthyroidism, 24-hour urine calcium to detect absorptive hypercalciuria, and serum protein electrophoresis in patients over 70 to screen for multiple myeloma 12.

Dental evaluation before starting long-term bisphosphonate therapy is recommended by the American Dental Association because the incidence of MRONJ, while low (estimated at 0.001% to 0.01% per year for oral bisphosphonates), increases with extractions performed during active therapy 13.

Medi-Cal and Insurance Coverage for Alendronate in California

Medi-Cal (California's Medicaid program) covers generic alendronate 70 mg for osteoporosis when prior authorization (PA) requirements are met. The standard PA criteria require a confirmed osteoporosis diagnosis (ICD-10 code M81.0 for age-related osteoporosis without fracture or M80.x for pathological fracture), a DXA T-score at or below -2.5 at the hip or lumbar spine, or a fragility fracture history 14.

The prescriber submits the PA through the Medi-Cal Rx portal along with the DXA report and applicable clinical notes. Processing time is typically 5 to 14 business days, although urgent PA requests for patients with recent fractures may be processed within 72 hours 14.

Most commercial insurers in California, including Anthem Blue Cross, Blue Shield of California, and Kaiser Permanente plans, cover generic alendronate on Tier 1 without PA, requiring only a valid prescription. Patients on Medicare Part D should check their plan's formulary; alendronate appears on Tier 1 or Tier 2 in the majority of California-available Part D plans, with a typical copay of $0 to $10 per month 15.

For uninsured or underinsured California patients, GoodRx coupons bring the cash price of generic alendronate 70 mg (four tablets per month) to approximately $4 to $9 at Costco Pharmacy, CVS, Walgreens, and Rite Aid locations across the state.

How to Fill a Fosamax Prescription at a California Pharmacy

Any California-licensed retail pharmacy may dispense alendronate on a valid prescription from a California-licensed prescriber. The drug is not a controlled substance, so there are no DEA or CURES reporting requirements that would complicate electronic prescribing or mail-order delivery 16.

California 503A compounding pharmacies are licensed by the California State Board of Pharmacy and may prepare customized alendronate formulations, for example in liquid form for patients who cannot swallow tablets, provided a valid patient-specific prescription exists. The formulation must not be a copy of a commercially available product unless the commercial version is unavailable or the patient has a documented medical need for the alternative form 17.

Mail-order pharmacies licensed in California may ship alendronate to any California address. Standard shipping is typically 3 to 7 business days; most mail-order programs offer 90-day supplies to reduce per-unit cost. After a telehealth visit, the electronic prescription is transmitted directly to the pharmacy of the patient's choice, and the first fill commonly arrives within 5 to 10 business days of the initial telehealth appointment.

Transfers of existing alendronate prescriptions to California pharmacies are permitted under California pharmacy law. A pharmacist in another state may transfer a non-controlled prescription to a California pharmacy once, provided refills remain on the original prescription 16.

How Long Does It Take to Get Fosamax in California

The total time from initial contact to first dose depends on whether the patient has a current DXA scan and labs in hand.

Patients with current records (DXA within 24 months, labs within 90 days) who book a telehealth visit can expect to complete their encounter in one day, receive the electronic prescription within 24 hours, and have the medication dispensed from a local California pharmacy the same or next business day. Total time: 1 to 3 days.

Patients who need labs first should allow 3 to 7 days for the lab draw and result turnaround at major California commercial labs (Quest Diagnostics, LabCorp). Adding the telehealth visit and prescription processing brings the total to roughly 5 to 10 days before the first dose.

Patients who also need a DXA scan should expect an additional 1 to 3 weeks for scheduling and imaging, depending on their county. Rural Northern California counties and parts of the Central Valley have longer DXA wait times than the Bay Area or Los Angeles metro area 18.

Medi-Cal patients awaiting prior authorization should add 5 to 14 business days. Some California clinicians write a short 30-day bridge prescription using cash-pay generic alendronate (approximately $4) while the PA is processed, an approach that aligns with AACE guidance on minimizing treatment delay in high-risk patients 4.

Dosing, Administration, and Drug Holidays

The standard adult dose is alendronate 70 mg once weekly, taken on the same day each week, at least 30 minutes before the first food, drink (other than plain water), or medication of the day 3. The patient must remain upright (sitting or standing) for at least 30 minutes after swallowing the tablet to minimize the risk of esophageal irritation. This administration requirement is the most common source of non-adherence.

A daily dose option, alendronate 10 mg, exists for patients who prefer it or who have specific Medi-Cal formulary restrictions, though the weekly formulation is preferred for adherence 19.

After 5 years of oral bisphosphonate therapy, AACE guidelines and the American Society for Bone and Mineral Research (ASBMR) task force suggest reassessing fracture risk 20. Patients at moderate risk may take a drug holiday of 2 to 3 years, while patients with hip T-score at or below -2.5 or prior vertebral fracture should continue therapy or transition to an anabolic agent such as teriparatide (Forteo) or romosozumab (Evenity) 20. The long skeletal half-life of alendronate means residual antifracture benefit persists even during a drug holiday, as demonstrated in the FLEX trial (N=1,099), which showed continued vertebral fracture protection in patients who paused after 5 years of treatment 21.

Safety, Side Effects, and Contraindications

Alendronate's most common adverse effects are gastrointestinal: esophageal irritation, nausea, abdominal discomfort, and, in some patients, esophagitis or esophageal ulceration if administration instructions are not followed 22. Patients with Barrett's esophagus or active esophageal disease are typically switched to intravenous zoledronic acid 5 mg (Reclast), dosed once yearly.

Two rare but serious adverse effects warrant mention. Atypical femoral fractures (AFFs) are low-energy subtrochanteric fractures associated with long-term bisphosphonate use; the absolute risk is approximately 3.2 to 50 per 100,000 person-years depending on duration of use 23. Medication-related osteonecrosis of the jaw (MRONJ) occurs in an estimated 0.001% to 0.01% per year with oral bisphosphonate use 13. Both risks are substantially lower with the 5-year oral course than with intravenous bisphosphonates used in oncology settings.

Hard contraindications to alendronate include abnormalities of the esophagus that delay esophageal emptying, inability to stand or sit upright for 30 minutes, hypocalcemia, and eGFR <35 mL/min/1.73 m² 3.

Monitoring While on Alendronate in California

After starting alendronate, California clinicians typically schedule a follow-up at 3 to 6 months to assess tolerability and adherence 4. Serum calcium and 25-OH vitamin D are rechecked at 3 months if baseline values were borderline. DXA is repeated at 2 years to assess treatment response; a loss of BMD of more than 4% at the hip despite good adherence warrants evaluation for secondary causes or transition to an anabolic agent 24.

Bone turnover markers, specifically serum C-terminal telopeptide (CTX) or urinary N-telopeptide (NTX), may be checked at 3 to 6 months to confirm biochemical response. A 25% to 50% reduction in CTX from baseline indicates effective osteoclast suppression 25. Some California endocrinologists use serial CTX measurements as a proxy for adherence in patients whose self-report is uncertain.

Calcium and vitamin D supplementation should be continued throughout treatment. The National Osteoporosis Foundation recommends 1,000 to 1 to 200 mg of elemental calcium daily (from diet and supplements combined) and 800 to 1 to 000 IU of vitamin D3 daily for adults on antiresorptive therapy 26.